{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:18:45Z","timestamp":1792678725849,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T00:00:00Z","timestamp":1478131200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12879-016-1955-7","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T07:51:30Z","timestamp":1478159490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration"],"prefix":"10.1186","volume":"16","author":[{"name":"on behalf of the Lyon BJI study group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Peeters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Ader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Boibieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Bouaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Karsenty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Forestier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Lustig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Chidiac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-6162","authenticated-orcid":false,"given":"Florent","family":"Valour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,3]]},"reference":[{"key":"1955_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SYC Tong","year":"2015","unstructured":"Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28:603\u201361.","journal-title":"Clin Microbiol Rev"},{"key":"1955_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cis803","volume":"56","author":"DR Osmon","year":"2013","unstructured":"Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:e1\u201325.","journal-title":"Clin Infect Dis"},{"key":"1955_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/sur.2013.258","volume":"16","author":"M Tit\u00e9cat","year":"2015","unstructured":"Tit\u00e9cat M, Senneville E, Wallet F, Dez\u00e8que H, Migaud H, Courcol RJ, Lo\u00efez C. Microbiologic profile of Staphylococci isolated from osteoarticular infections: evolution over ten years. Surg Infect. 2015;16:77\u201383.","journal-title":"Surg Infect"},{"key":"1955_CR4","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1128\/AAC.02032-13","volume":"58","author":"F Valour","year":"2014","unstructured":"Valour F, Karsenty J, Bouaziz A, Ader F, Tod M, Lustig S, Laurent F, Ecochard R, Chidiac C, Ferry T. Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58:746\u201355.","journal-title":"Antimicrob Agents Chemother"},{"key":"1955_CR5","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1128\/AAC.00341-09","volume":"53","author":"S Svetitsky","year":"2009","unstructured":"Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53:4069\u201379.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 5","key":"1955_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/1120009X.2000.11782314","volume":"12","author":"MJ Wood","year":"2000","unstructured":"Wood MJ. Comparative safety of teicoplanin and vancomycin. J Chemother. 2000;12 Suppl 5:21\u20135.","journal-title":"J Chemother"},{"key":"1955_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","volume":"48","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sorgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48:89\u2013124.","journal-title":"Clin Pharmacokinet"},{"key":"1955_CR8","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/AAC.37.12.2693","volume":"37","author":"F Lalla De","year":"1993","unstructured":"De Lalla F, Novelli A, Pellizzer G, Milocchi F, Viola R, Rigon A, Stecca C, Dal Pizzol V, Fallani S, Periti P. Regional and systemic prophylaxis with teicoplanin in monolateral and bilateral total knee replacement procedures: study of pharmacokinetics and tissue penetration. Antimicrob Agents Chemother. 1993;37:2693\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"54","key":"1955_CR9","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1093\/cid\/cis346","volume":"2012","author":"BA Lipsky","year":"2012","unstructured":"Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E. Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;2012(54):e132\u201373.","journal-title":"Clin Infect Dis"},{"key":"1955_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351.","journal-title":"J Clin Epidemiol"},{"key":"1955_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0924-8579(96)00009-X","volume":"7","author":"V Dacquet","year":"1996","unstructured":"Dacquet V. Treatment of bone and joint infection with teicoplanin: a retrospective analysis of 50 cases. Int J Antimicrob Agents. 1996;7:49\u201351.","journal-title":"Int J Antimicrob Agents"},{"key":"1955_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s101560050005","volume":"5","author":"J LeFrock","year":"1999","unstructured":"LeFrock J, Ristuccia A. Teicoplanin in the treatment of bone and joint infections: an open study. J Infect Chemother. 1999;5:32\u20139.","journal-title":"J Infect Chemother"},{"key":"1955_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/jac\/25.3.435","volume":"25","author":"P Marone","year":"1990","unstructured":"Marone P, Concia E, Andreoni M, Suter F, Cruciani M. Treatment of bone and soft tissue infections with teicoplanin. J Antimicrob Chemother. 1990;25:435\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1955_CR14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/00007611-199308000-00009","volume":"86","author":"WG Weinberg","year":"1993","unstructured":"Weinberg WG. Safety and efficacy of teicoplanin for bone and joint infections: results of a community-based trial. South Med J. 1993;86:891\u20137.","journal-title":"South Med J"},{"key":"1955_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/jac\/45.6.835","volume":"45","author":"I Harding","year":"2000","unstructured":"Harding I, MacGowan AP, White LO, Darley ES, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother. 2000;45:835\u201341.","journal-title":"J Antimicrob Chemother"},{"key":"1955_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","volume":"39","author":"AP Wilson","year":"2000","unstructured":"Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000;39:167\u201383.","journal-title":"Clin Pharmacokinet"},{"key":"1955_CR17","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1128\/AAC.34.12.2392","volume":"34","author":"RN Greenberg","year":"1990","unstructured":"Greenberg RN. Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother. 1990;34:2392\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1955_CR18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cid\/cir402","volume":"53","author":"E Senneville","year":"2011","unstructured":"Senneville E, Joulie D, Legout L, Valette M, Dezeque H, Beltrand E, Rosel\u00e9 B, d\u2019Escrivan T, Lo\u00efez C, Caillaux M, Yazdanpanah Y, Maynou C, Migaud H. Outcome and predictors of treatment failure in total hip\/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis. 2011;53:334\u201340.","journal-title":"Clin Infect Dis"},{"key":"1955_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1086\/499234","volume":"42","author":"CE Marculescu","year":"2006","unstructured":"Marculescu CE, Berbari EF, Hanssen AD, Steckelberg JM, Harmsen SW, Mandrekar JN, Osmon DR. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis. 2006;42:471\u20138.","journal-title":"Clin Infect Dis"},{"key":"1955_CR20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/BLO.0b013e3181123d4e","volume":"461","author":"CD Salgado","year":"2007","unstructured":"Salgado CD, Dash S, Cantey JR, Marculescu CE. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin Orthop Relat Res. 2007;461:48\u201353.","journal-title":"Clin Orthop Relat Res"},{"key":"1955_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1128\/AAC.00700-07","volume":"52","author":"SH Kim","year":"2008","unstructured":"Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52:192\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1955_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/jac\/dkg186","volume":"51","author":"AD Tice","year":"2003","unstructured":"Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother. 2003;51:1261\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1955_CR23","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0","author":"The European Committee on Antimicrobial Susceptibility Testing","year":"2016","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. 2016."},{"key":"1955_CR24","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jac\/dkr531","volume":"67","author":"HJ Chang","year":"2012","unstructured":"Chang HJ, Hsu PC, Yang CC, Siu LK, Kuo AJ, Chia JH, Wu TL, Huang CT, Lee MH. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study. J Antimicrob Chemother. 2012;67:736\u201341.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"1955_CR25","first-page":"40","volume":"62","author":"C Pensotti","year":"2002","unstructured":"Pensotti C, Nacinovich F, Vidiella G, Carbone E, Marin M, Di St\u00e9fano C, Stamboulian D. Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients. Medicina. 2002;62 Suppl 2:40\u20137.","journal-title":"Medicina"},{"issue":"Suppl 1","key":"1955_CR26","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/S0399-077X(04)90084-4","volume":"34","author":"E Senneville","year":"2004","unstructured":"Senneville E, Legout L, Corroyer B, Yazdanpanah Y, Mouton Y. Adequate use of teicoplanin in bone and joint infections. Med Mal Infect. 2004;34 Suppl 1:S99\u2013102.","journal-title":"Med Mal Infect"},{"key":"1955_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jinf.2013.08.018","volume":"68","author":"PC Matthews","year":"2014","unstructured":"Matthews PC, Chue AL, Wyllie D, Barnett A, Isinkaye T, Jefferies L, Lovering A, Scarborough M. Increased teicoplanin doses are associated with improved serum levels but not drug toxicity. J Infect. 2014;68:43\u20139.","journal-title":"J Infect"},{"key":"1955_CR28","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jinf.2007.07.012","volume":"55","author":"PC Matthews","year":"2007","unstructured":"Matthews PC, Taylor A, Byren I, Atkins BL. Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic? J Infect. 2007;55:408\u201313.","journal-title":"J Infect"},{"key":"1955_CR29","doi-asserted-by":"crossref","unstructured":"El Samad Y, Lanoix JP, Bennis Y, Diouf M, Saroufim C, Brunschweiler B, Rousseau F, Joseph C, Hamdad F, Ait Amer Meziane M, Routier S, Schmit JL. Tolerability and plasma drug levels monitoring of prolonged subcutaneous teicoplanin treatment for bone and joint infections. Antimicrob Agents Chemother. 2016. (ahead of print).","DOI":"10.1128\/AAC.00351-16"},{"key":"1955_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/sur.2012.078","volume":"14","author":"AL Sims","year":"2013","unstructured":"Sims AL, Baker P, Bellamy R, McMurtry IA. Outpatient parenteral antibiotic therapy in primary hip and knee arthroplasty infection managed with debridement and retention of prosthesis: a retrospective cohort study. Surg Infect. 2013;14:293\u20136.","journal-title":"Surg Infect"},{"key":"1955_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/jac\/dkg061","volume":"51","author":"D Nathwani","year":"2003","unstructured":"Nathwani D, Barlow GD, Ajdukiewicz K, Gray K, Morrison J, Clift B, France AJ, Davey P. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. J Antimicrob Chemother. 2003;51:391\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"1955_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1179\/joc.2002.14.1.71","volume":"14","author":"L Lazzarini","year":"2002","unstructured":"Lazzarini L, Tramarin A, Bragagnolo L, Tositti G, Manfrin V, de LF. Three-times weekly teicoplanin in the outpatient treatment of acute methicillin-resistant staphylococcal osteomyelitis: a pilot study. J Chemother. 2002;14:71\u20135.","journal-title":"J Chemother"},{"key":"1955_CR33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/BF01690746","volume":"14","author":"W Graninger","year":"1995","unstructured":"Graninger W, Wenisch C, Wiesinger E, Menschik M, Karimi J, Presterl E. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis. 1995;14:643\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1955_CR34","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/jac\/dkq445","volume":"66","author":"CL Mackintosh","year":"2011","unstructured":"Mackintosh CL, White HA, Seaton RA. Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service. J Antimicrob Chemother. 2011;66:408\u201315.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-016-1955-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T03:15:40Z","timestamp":1601176540000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-016-1955-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1955"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-1955-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,3]]},"article-number":"622"}}